Legend Financial Statements From 2010 to 2025

LEGN Stock  USD 37.88  0.06  0.16%   
Legend Biotech financial statements provide useful quarterly and yearly information to potential Legend Biotech Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Legend Biotech financial statements helps investors assess Legend Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Legend Biotech's valuation are summarized below:
Gross Profit
-20.9 M
Profit Margin
(0.28)
Market Capitalization
B
Enterprise Value Revenue
9.8775
Revenue
627.2 M
We have found one hundred twenty available fundamental ratios for Legend Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Legend Biotech's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 5.5 B. In addition to that, Enterprise Value is likely to drop to about 5.1 B

Legend Biotech Total Revenue

658.6 Million

Check Legend Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Legend Biotech's main balance sheet or income statement drivers, such as Tax Provision of 19.8 M, Depreciation And Amortization of 12.8 M or Interest Expense of 22.7 M, as well as many indicators such as Price To Sales Ratio of 4.51, Dividend Yield of 0.0 or PTB Ratio of 2.72. Legend financial statements analysis is a perfect complement when working with Legend Biotech Valuation or Volatility modules.
  
Check out the analysis of Legend Biotech Correlation against competitors.

Legend Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.7 B647.9 M
Slightly volatile
Short and Long Term Debt Total368.1 M350.6 M91.9 M
Slightly volatile
Other Current Liabilities146.5 M164.2 M83.4 M
Slightly volatile
Total Current Liabilities216.2 M277.6 M134.6 M
Slightly volatile
Other Liabilities6.7 M7.1 M155 M
Slightly volatile
Property Plant And Equipment Net129.4 M201.6 M68.2 M
Slightly volatile
Current Deferred Revenue45.9 M47.4 M37 M
Slightly volatile
Accounts Payable39.1 M37.2 M12.1 M
Slightly volatile
Cash521.2 M286.7 M270.4 M
Slightly volatile
Non Current Assets Total200.4 M386.2 M107 M
Slightly volatile
Non Currrent Assets Other5.8 M6.1 M17.6 M
Slightly volatile
Other Assets1.091.159.4 M
Pretty Stable
Cash And Short Term Investments718.1 M1.1 B372.2 M
Slightly volatile
Net Receivables82.7 M124.9 M156.9 M
Slightly volatile
Common Stock Shares Outstanding156.9 M182.9 M138.9 M
Slightly volatile
Long Term Debt Total3.4 M5.8 M2.5 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.7 B647.9 M
Slightly volatile
Non Current Liabilities Total328.2 M352 M246 M
Slightly volatile
Inventory25.1 M23.9 M5.3 M
Slightly volatile
Other Current Assets17.4 M12.4 MM
Slightly volatile
Total Liabilities544.4 M629.6 M380.6 M
Slightly volatile
Total Current Assets850.8 M1.3 B540.9 M
Slightly volatile
Short Term Debt2.6 M4.8 M1.4 M
Slightly volatile
Intangible Assets182.9 M174.2 M23.9 M
Slightly volatile
Common Stock30.8 K37 K24.7 K
Slightly volatile
Property Plant Equipment100.7 M184.9 M63.5 M
Slightly volatile
Common Stock Total Equity24.6 K31.1 K22.7 K
Slightly volatile
Short Term Investments877.7 M835.9 M147.3 M
Slightly volatile
Capital Lease Obligations51.9 M49.4 M13.9 M
Slightly volatile
Property Plant And Equipment Gross158.7 M245.2 M89 M
Slightly volatile
Capital Stock32.1 K37 K24.8 K
Slightly volatile
Net Working Capital697.1 MB404.7 M
Slightly volatile
Non Current Liabilities Other47.9 K50.4 K192.3 M
Slightly volatile
Long Term Debt265.1 M301.2 M159.6 M
Slightly volatile

Legend Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization12.8 M23.4 M6.7 M
Slightly volatile
Selling General Administrative143.6 M136.8 M35 M
Slightly volatile
Selling And Marketing Expenses154.9 M147.5 M41.9 M
Slightly volatile
Total Revenue658.6 M627.2 M134.3 M
Slightly volatile
Other Operating Expenses407.6 M627.2 M215 M
Slightly volatile
Research Development262.3 M413.5 M139.2 M
Slightly volatile
Total Operating Expenses285.6 M392.7 M151.9 M
Slightly volatile
Interest Income64.3 M61.2 M15 M
Slightly volatile
Reconciled Depreciation14.6 M23.4 M7.6 M
Slightly volatile

Legend Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.1 M1.3 M1.4 M
Slightly volatile
Begin Period Cash Flow1.3 B1.3 B303.8 M
Slightly volatile
Other Cashflows From Financing Activities9.2 M9.7 M27.4 M
Slightly volatile
Depreciation12.8 M23.4 M6.7 M
Slightly volatile
Capital Expenditures13.4 M14.1 M14.8 M
Slightly volatile
Change To Operating Activities143.4 M136.6 M46.4 M
Slightly volatile
Total Cash From Financing Activities5.4 M5.7 M154.4 M
Slightly volatile
End Period Cash Flow521.2 M286.7 M270.4 M
Slightly volatile
Stock Based Compensation72.4 M68.9 M16 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.514.74364.2903
Slightly volatile
Days Sales Outstanding69.0472.6741.9 K
Slightly volatile
Stock Based Compensation To Revenue0.10.10990.0693
Slightly volatile
Capex To Depreciation0.570.60384.0329
Slightly volatile
EV To Sales9.119.5877127
Slightly volatile
Sales General And Administrative To Revenue0.230.21810.1914
Slightly volatile
Research And Ddevelopement To Revenue0.630.65931.181
Slightly volatile
Capex To Revenue0.02140.02250.1818
Slightly volatile
Cash Per Share3.396.13992.3406
Slightly volatile
Intangibles To Total Assets0.110.10430.0153
Slightly volatile
Current Ratio3.044.62434.0284
Pretty Stable
Receivables Turnover5.275.02241.2712
Slightly volatile
Capex Per Share0.07330.07710.1085
Slightly volatile
Revenue Per Share3.63.43030.8136
Slightly volatile
Interest Debt Per Share2.142.03560.5672
Slightly volatile
Debt To Assets0.220.20990.061
Slightly volatile
Graham Number0.30.350.3762
Slightly volatile
Operating Cycle1041101.9 K
Slightly volatile
Ebt Per Ebit0.821.071.0061
Very volatile
Long Term Debt To Capitalization0.240.22450.2094
Slightly volatile
Quick Ratio3.024.53824.0118
Pretty Stable
Net Income Per E B T1.181.11950.9026
Slightly volatile
Cash Ratio1.691.03281.1781
Slightly volatile
Cash Conversion Cycle49.3951.993710.1 K
Slightly volatile
Days Of Sales Outstanding69.0472.6741.9 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.311.09791.2767
Slightly volatile
Fixed Asset Turnover2.313.11144.721
Slightly volatile
Debt Ratio0.220.20990.061
Slightly volatile
Price Sales Ratio4.514.74364.2903
Slightly volatile
Asset Turnover0.390.37560.1436
Slightly volatile

Legend Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.5 B5.9 B4.6 B
Slightly volatile
Enterprise Value5.1 BB4.1 B
Slightly volatile

Legend Fundamental Market Drivers

Forward Price Earnings1000
Cash And Short Term Investments1.1 B

Legend Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Legend Biotech Financial Statements

Legend Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Legend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue47.4 M45.9 M
Total Revenue627.2 M658.6 M
Cost Of Revenue234.6 M181.4 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.22  0.23 
Research And Ddevelopement To Revenue 0.66  0.63 
Capex To Revenue 0.02  0.02 
Revenue Per Share 3.43  3.60 
Ebit Per Revenue(1.77)(1.86)

Pair Trading with Legend Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Legend Stock

  0.46VINC Vincerx PharmaPairCorr
  0.38DRRX Durect Earnings Call This WeekPairCorr
  0.33CDIOW Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:
Check out the analysis of Legend Biotech Correlation against competitors.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Revenue Per Share
3.43
Quarterly Revenue Growth
1.347
Return On Assets
(0.11)
Return On Equity
(0.15)
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.